BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11189510)

  • 81. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
    Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
    Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation.
    Testoni N; Martinelli G; Zaccaria A; Miggiano MC; Pelliconi S; Visani G; Manfroi S; Gherlinzoni F; Mangianti S; Tura S
    Bone Marrow Transplant; 1996 Dec; 18(6):1141-5. PubMed ID: 8971385
    [TBL] [Abstract][Full Text] [Related]  

  • 83. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia.
    Porcellini A; Manna A; Moretti L; Carotenuto M; Greco MM; Bodenizza C
    Bone Marrow Transplant; 1989 May; 4(3):331-3. PubMed ID: 2659120
    [No Abstract]   [Full Text] [Related]  

  • 85. New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis.
    Imrie KR; Dubé I; Prince HM; Girouard C; Crump M; Keating A
    Bone Marrow Transplant; 1998 Feb; 21(4):395-9. PubMed ID: 9509975
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
    Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
    J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Double intensification including autologous bone marrow transplantation (ABMT) in AML: long term follow-up and detection of residual disease.
    Dicke KA; Dicke-Evinger MJ; Spinolo JA; Estey EH; Kantarjian HM; Spitzer GS
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():27-34. PubMed ID: 2390639
    [No Abstract]   [Full Text] [Related]  

  • 88. [Autologous transplantation in acute lymphoblastic leukemia in adults].
    Piatkowska-Jakubas B; Wegrzyn J; Rucińska M; Skotnicki AB
    Przegl Lek; 1999; 56 Suppl 1():52-6. PubMed ID: 10494183
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Autologous bone marrow transplantation for extramedullary relapse in childhood leukemia. The AIEOP Group and the FONOP. Italian Association of Pediatric Hemato/Oncology.
    Messina C; Rondelli R; Valsecchi MG; Rossetti F; Miniero R; Meloni G; Locatelli F; Aricò M; Testi AM; Dini G; Arrighini A; Manfredini L; Dallorso S; Porta F; Uderzo C; Santoro N; Werner B; De Rossi G; Loiacono G; Andolina M; Lippi A; Favre C; Amici A; Lo Curto M; Masera G
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():40-2. PubMed ID: 8932797
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Successful treatment of primary extramedullary leukemia (EML) of the uterus with radical surgery, chemotherapy, autologous bone marrow transplantation (BMT) and prophylactic local irradiation.
    Huter O; Brezinka C; Nachbaur D; Schwaighofer H; Lang A; Niederwieser D
    Bone Marrow Transplant; 1996 Sep; 18(3):663-4. PubMed ID: 8879638
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Allogenic bone marrow transplantation for leukemias and aplastic anemia.
    Tsai TW; Freytes CO
    Adv Intern Med; 1997; 42():423-51. PubMed ID: 9048126
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
    Russell S; Vowels M
    Transplant Proc; 1992 Feb; 24(1):183. PubMed ID: 1539236
    [No Abstract]   [Full Text] [Related]  

  • 93. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
    Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
    Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
    [TBL] [Abstract][Full Text] [Related]  

  • 94. ABMT for early isolated extramedullary relapse of childhood ALL.
    Rossetti F; Messina C; Miniero R; Busca A; Sotti G; Cesaro S; Zanesco L; Colleselli P; Scotti G [corrected to Sotti G]
    Bone Marrow Transplant; 1993 Jul; 12(1):37-41. PubMed ID: 8374535
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Double autologous bone marrow transplantation in acute myeloid leukaemia.
    Gribben JG; Goldstone AH; Linch DC; MacMillan AK; Richards JD
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():209-11. PubMed ID: 2653506
    [No Abstract]   [Full Text] [Related]  

  • 96. TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission.
    Biagi E; Rovelli A; Balduzzi A; De Lorenzo P; Tagliabue A; Uderzo C
    Bone Marrow Transplant; 2000 Dec; 26(11):1260-2. PubMed ID: 11149746
    [No Abstract]   [Full Text] [Related]  

  • 97. Hematological recovery after autologous bone marrow transplantation in acute leukemia: predictive factors.
    Canals C; Marti JM; Martinez E; Sierra J; Punti C; Granena A; Domingo A; Cubells J; Brunet S; Badell I
    J Hematother; 1993; 2(1):75-85. PubMed ID: 7921968
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Aggressive chemotherapy for acute leukemia relapsed after transplantation.
    Sica S; Salutari P; Di Mario A; D'Onofrio G; Etuk B; Leone G
    Leuk Lymphoma; 1994 Sep; 15(1-2):131-4. PubMed ID: 7858490
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Are new conditioning regimens for transplants in acute myelogenous leukemia better?
    Aurer I; Gale RP
    Bone Marrow Transplant; 1991 Apr; 7(4):255-61. PubMed ID: 2070130
    [TBL] [Abstract][Full Text] [Related]  

  • 100. High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland.
    Regazzoni S; Marini G; Grob A; Pedrazzini A; Goldhirsch A; Castelli D; Cavalli F; Ghielmini M
    Bone Marrow Transplant; 1997 Jan; 19(1):3-7. PubMed ID: 9012924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.